

# NYRx Opioid Dependence Agents

On December 22, 2021, Governor Hochul signed Chapter 720 of the Laws of 2021, which amends Social Services Law and the Public Health Law, in relation to medication for the treatment of substance use disorders. **As of March 22, 2022**, prior authorization (PA) has not been required for medications used for the treatment of substance use disorder prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder. **Prescriptions written outside of accepted guidelines may be subject to PA.**

## Opioid Antagonists and Opioid Dependence Agents – Injectable

Opioid Antagonists and Opioid Dependence Agents – Injectable do not have any additional coverage parameters.

Medication Assisted Treatment (MAT) Formulary	
**Prior authorization will not be required when prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.**	
Drugs	Coverage Parameters
<b>Opioid Antagonists</b>	
Kloxxado™ naloxone (syringe, vial, nasal spray) naloxone (nasal spray) OTC naltrexone Narcan® (nasal spray) Narcan® OTC Opvee® Zimhi™**	n/a
<b>Opioid Dependence Agents – Injectable</b>	
Brixadi™ Vivitrol® Sublocade™	n/a

## Opioid Dependence Agents – Oral/Transmucosal

Medication Assisted Treatment (MAT) Formulary	
**Prior authorization will not be required when prescribed according to generally accepted national professional guidelines for the treatment of a substance use disorder.**	
Drugs	Coverage Parameters
<b>Opioid Dependence Agents – Oral/Transmucosal <sup>F/Q/D</sup></b>	
buprenorphine (tablet) buprenorphine/naloxone (tablet) Suboxone® (film) buprenorphine/naloxone (film) Zubsolv®	<p><b>QUANTITY LIMIT:</b></p> <ul style="list-style-type: none"> <li>• <b>buprenorphine sublingual (SL):</b> Eight tablets dispensed as a 2-day supply; not to exceed 32 mg per day</li> <li>• <b>buprenorphine / naloxone tablet and film (Suboxone®</b> up to 8mg/2mg strength, <b>Zubsolv®</b> up to 5.7 mg/1.4 mg strength); Four sublingual tablets or films per day; maximum of 120 tablets or films dispensed as a 30-day supply, not to exceed 32 mg-8 mg of Suboxone®, or its equivalent per day</li> <li>• <b>buprenorphine/naloxone tablet: Suboxone®</b> 12mg/3mg, <b>Zubsolv®</b> 8.6 mg/2.1 mg and <b>Zubsolv®</b> 11.4 mg/2.9 mg strength: Maximum of 60 tablets dispensed as a 30-day supply</li> </ul> <p><b>RELATED CLINICAL CRITERIA (CC)</b></p> <ul style="list-style-type: none"> <li>• PA required for initiation of <b>opioid therapy</b> for patients on established opioid dependence therapy</li> <li>• PA required for initiation of a <b>CNS stimulant</b> for patients established on opioid dependence therapy **</li> </ul>

## Quantity Limit

- Buprenorphine sublingual (SL): Eight tablets dispensed as a two-day supply; not to exceed 32 mg per day.
- Buprenorphine/ naloxone tablet and film (Suboxone® up to 8mg/2mg strength, Zubsolv® up to 5.7 mg/1.4 mg strength).
  - Four sublingual tablets or films per day; maximum of 120 tablets or films dispensed as a 30-day supply, not to exceed 32 mg-8 mg of Suboxone®, or its equivalent per day.
- Buprenorphine/naloxone tablet Suboxone® 12mg/3mg, Zubsolv® 8.6 mg/2.1 mg and Zubsolv® 11.4 mg/2.9 mg strength: Maximum of 60 tablets dispensed as a 30-day supply.

## Related Prior Authorization Criteria

- Opioids – Prior authorization required for initiation of opioid therapy for patients on established opioid dependence therapy.
- Central Nervous System (CNS) Stimulants – Prior authorization required for initiation of CNS stimulant therapy for patients on established opioid dependence therapy.

## Methadone

Methadone, when used for detoxification or maintenance treatment of opioid addiction, must be dispensed from a Methadone Maintenance Treatment Program.

## Resources

- [New York State Medicaid Update](#)
- [NYRx Drug Class Coverage Overview: Long-Acting Opioids](#)
- [NYRx Drug Class Coverage Overview: Short Acting Opioids](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Prior Authorization Submission Guide](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 or by email at [NYRxEO@primetherapeutics.com](mailto:NYRxEO@primetherapeutics.com) from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays. For more information, visit the [NYRx Education & Outreach website](#).